Critical Gaps Found in Genetic Research Result Follow-Up

What Is the Impact of Returning Genetic Research Results?

Penn Medicine Biobank researchers have reported critical gaps in patient follow-up after returning actionable genetic research results, raising concerns about the clinical benefits of such programs. In their pilot study, only 57% of participants completed clinical confirmation testing of their research results, and among those who did, just 67% attended recommended clinical genetics appointments to receive expert guidance on their findings.

The findings emerge from a retrospective electronic health record (EHR) review that analyzed outcomes among biobank participants who received actionable genetic findings through a randomized pilot study. The research team tracked three distinct participant groups: those who completed both confirmation testing and clinical genetics follow-up; those who confirmed results but skipped genetics appointments; and those who received results but never pursued confirmation testing. The analysis revealed stark differences in clinical outcomes between groups, with most participants who completed all recommended steps showing evidence of appropriate screening and preventive care, while those who skipped steps rarely showed documentation of following gene-specific recommendations. These results highlight significant challenges in translating genetic research discoveries into meaningful clinical action. The research team noted particular concerns about participants with cardiovascular genetic findings, who were less likely to complete all recommended follow-up steps compared to those with cancer-related variants. Additionally, male participants demonstrated significantly lower completion rates across all follow-up steps compared to female participants, suggesting potential gender-based disparities in engagement with genetic results. These findings suggest that simply returning actionable genetic research results without ensuring proper clinical follow-up may fail to deliver anticipated health benefits. Despite the growing enthusiasm for returning genetic findings from biobanks and research studies, these results underscore the complexity of implementation and the need for structured clinical pathways to ensure appropriate medical management following result disclosure.

How Did Past Efforts Shape Current Clinical Strategies?

The study represents an important contribution to the ongoing debate about returning individual research results from biobanks, which has gained momentum as large-scale genomic studies identify potentially actionable findings in research participants. Unlike clinical genetic testing, where patients actively seek genetic information and are prepared for results, biobank participants often enroll without expecting to receive individual findings. This creates unique challenges for communicating results and ensuring appropriate follow-up care. Prior research has documented high theoretical interest in receiving genetic research results among biobank participants, typically exceeding 80% in survey studies. However, actual uptake rates when results are offered have been considerably lower, generally around 50% in biobank populations. The Penn Medicine study adds crucial longitudinal data to this discussion by examining what happens after results are returned, revealing significant drop-off at each subsequent step in the clinical follow-up pathway. The team's two-step approach—first offering pre-disclosure education with opt-out options, then randomizing participants to either digital disclosure or genetic counselor disclosure—was designed to accommodate participants who may not have anticipated receiving genetic findings when they initially enrolled in the biobank. This approach reflects evolving best practices in the field, balancing respect for participant autonomy with the potential clinical benefits of returning actionable genetic information.

The electronic health record review methodology allowed researchers to capture real-world clinical outcomes following result disclosure, rather than relying solely on participant self-report. Researchers systematically examined medical records for evidence of adherence to gene-specific guidelines, communication with healthcare providers, and completion of recommended screening and preventive measures. Among participants who completed all steps, including clinical genetics consultation, 69% showed evidence of following appropriate screening and prevention recommendations. However, the researchers noted several barriers to care even in this group, including insurance challenges, logistical difficulties related to comorbid conditions, and competing healthcare priorities. More concerning were the findings among participants who didn't complete all steps—75% of those who confirmed their results but skipped genetics consultation had no evidence of discussing their findings with other healthcare providers or implementing appropriate screening. Similarly, 71% of those who never confirmed their research results showed no evidence of provider discussion about their genetic findings. These patterns suggest that the clinical genetics consultation may be a critical component for translating genetic information into appropriate medical care, rather than an optional step as sometimes characterized in return of results programs.

What Insights Do Experts Provide?

"These findings highlight the importance of not just returning results, but ensuring a seamless handoff to clinical care teams who can support implementation of appropriate screening and prevention," noted the researchers. "Without this critical step, the potential benefits of identifying actionable genetic variants may not be realized." The team emphasized that barriers to completing recommended follow-up were similar to those seen in clinical genetic testing, including insurance limitations, transportation challenges, and competing healthcare priorities. The study also raised important questions about the requirement for CLIA confirmation testing before research results can guide medical management. While this regulatory requirement ensures analytical validity, it creates an additional barrier that many participants fail to overcome. The researchers acknowledged this tension, noting that restricting return of results to only CLIA-certified labs would significantly reduce opportunities to identify actionable variants, as previous studies suggest nearly half of participants with actionable findings would not have met clinical criteria for genetic testing in usual care.

Can Market Innovations Close the Follow-Up Gap?

The study findings have implications for companies developing biobank return of results programs, clinical decision support tools, and digital health platforms aimed at improving genetic result communication. Several market leaders are developing solutions to address the gaps identified in this research, including telehealth-based genetic counseling services, EHR-integrated clinical decision support, and automated follow-up systems to improve adherence to genetic screening recommendations. Industry analysts suggest the market for genetic result management solutions could exceed $500 million by 2025, driven by the growing adoption of genomic medicine and the increasing recognition that result disclosure alone is insufficient to drive clinical benefit. Companies like Invitae, Genome Medical, and Ambry Genetics have developed platforms combining digital education with telehealth counseling, while EHR vendors like Epic and Cerner are integrating genetic information into clinical workflows. The Penn Medicine findings suggest that hybrid models combining digital tools with access to genetic expertise may be most effective, particularly for biobank participants who weren't initially seeking genetic information.

What Does the Future Hold for Genomic Medicine?

Looking ahead, the researchers called for systematic longitudinal studies to more comprehensively evaluate outcomes following return of actionable genetic research results. They suggested several potential interventions to improve follow-up rates, including integrating genetics expertise directly into primary care, expanding telehealth-based genetic counseling, using EHR alerts to prompt follow-up care, and enhancing logistical support such as transportation assistance and insurance navigation. The team also emphasized the need to better understand communication of genetic information to relatives, as cascade testing of family members is a key benefit of returning actionable results. Their EHR review found minimal evidence of cascade testing being pursued, suggesting another potential gap in realizing the full benefits of genetic result disclosure. The researchers acknowledged the exploratory nature of their findings, noting that lack of documentation in the EHR doesn't definitively mean discussions or screening didn't occur elsewhere. Nevertheless, the patterns observed suggest significant opportunities to improve the clinical impact of returning genetic research results.

Industry Context: This study comes amid growing investment in large-scale biobank initiatives and increasing regulatory attention to the return of individual research results. As precision medicine initiatives expand globally and genomic data becomes more integrated into healthcare, these findings highlight a critical implementation gap that technology developers and healthcare systems must address. The results suggest that simply identifying actionable variants is insufficient without robust clinical pathways to support result confirmation, expert interpretation, and implementation of appropriate screening and prevention. Companies developing solutions in this space will need to address not just the technical aspects of result disclosure but the entire clinical journey from research finding to preventive action.

Summary

A retrospective study by Penn Medicine Biobank researchers has revealed significant gaps in patient follow-up after receiving actionable genetic research results, with only 57% of participants completing clinical confirmation testing and just 67% of those attending recommended genetics appointments. The electronic health record review tracked three participant groups and found that most who completed all recommended steps showed evidence of appropriate screening and preventive care, while those who skipped steps rarely followed gene-specific recommendations. The research highlighted particular concerns about cardiovascular genetic findings and gender-based disparities, with male participants showing significantly lower completion rates. These findings underscore that simply returning genetic research results without structured clinical pathways may fail to deliver anticipated health benefits. The study examined real-world clinical outcomes following result disclosure through a two-step approach involving pre-disclosure education and randomized disclosure methods. Among participants completing all steps including clinical genetics consultation, 69% showed evidence of following screening recommendations, but 75% of those who confirmed results without genetics consultation showed no evidence of provider discussion about their findings. The researchers emphasized the critical importance of seamless handoff to clinical care teams and raised questions about CLIA confirmation testing requirements that create additional barriers. The findings have significant implications for the growing genetic result management market, projected to exceed $500 million by 2025, with companies developing solutions including telehealth genetic counseling, EHR-integrated decision support, and automated follow-up systems. The study calls for systematic longitudinal research and interventions such as integrating genetics expertise into primary care, expanding telehealth counseling, and enhancing logistical support to improve follow-up rates and realize the full clinical benefits of returning actionable genetic research results.